Metformin and empagliflozin modulate monoamine oxidase-related oxidative stress and improve vascular function in human mammary arteries.
Empagliflozin
Endothelial dysfunction
Human mammary arteries
Metformin
Monoamine oxidases
Overweight patients
Oxidative stress
Journal
Molecular and cellular biochemistry
ISSN: 1573-4919
Titre abrégé: Mol Cell Biochem
Pays: Netherlands
ID NLM: 0364456
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
04
10
2022
accepted:
05
12
2022
medline:
21
7
2023
pubmed:
31
12
2022
entrez:
30
12
2022
Statut:
ppublish
Résumé
Monoamine oxidases (MAOs), mitochondrial enzymes with two isoforms, A and B, have been recently recognized as significant contributors to oxidative stress in the cardiovascular system. The present study was purported to assess the effect of metformin and empagliflozin on MAO expression, oxidative stress and vascular reactivity in internal mammary arteries harvested from overweight patients with coronary heart disease subjected to bypass grafting. Vascular rings were prepared and acutely incubated (12 h) with high glucose (GLUC, 400 mg/dL) or angiotensin II (AII, 100 nM) and metformin (10 µM) and/or empagliflozin (10 µM) and used for the assessment of MAO expression (qRT-PCR and immune histochemistry), reactive oxygen species (ROS, confocal microscopy and spectrophotometry), and vasomotor function (myograph). Ex vivo stimulation with GLUC or AII increased both MAOs expression, ROS production and impaired relaxation to acetylcholine (ACh) of the vascular rings. All effects were alleviated by incubation with each antidiabetic drug; no cumulative effect was obtained when the drugs were applied together. In conclusion, MAO-A and B are upregulated in mammary arteries after acute stimulation with GLUC and AII. Endothelial dysfunction and oxidative stress were alleviated by either metformin or empagliflozin in both stimulated and non-stimulated vascular samples harvested from overweight cardiac patients.
Identifiants
pubmed: 36583793
doi: 10.1007/s11010-022-04633-8
pii: 10.1007/s11010-022-04633-8
doi:
Substances chimiques
Reactive Oxygen Species
0
empagliflozin
HDC1R2M35U
Metformin
9100L32L2N
Monoamine Oxidase
EC 1.4.3.4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1939-1947Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Yun JS, Ko SH (2021) Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes. Metabolism 123:154838. https://doi.org/10.1016/j.metabol.2021.154838
doi: 10.1016/j.metabol.2021.154838
pubmed: 34333002
Ma CX, Ma XN, Guan CH, Li YD, Mauricio D, Fu SB (2022) Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management. Cardiovasc Diabetol 21:74. https://doi.org/10.1186/s12933-022-01516-6
doi: 10.1186/s12933-022-01516-6
pubmed: 35568946
pmcid: 9107726
Joseph JJ, Deedwania P, Acharya T, Aguilar D, Bhatt DL, Chyun DA, Di Palo KE, Golden SH, Sperling LS (2022) Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the American Heart Association. Circulation 145:e722–e759. https://doi.org/10.1161/cir.0000000000001040
doi: 10.1161/cir.0000000000001040
pubmed: 35000404
Mosenzon O, Alguwaihes A, Leon JLA, Bayram F, Darmon P, Davis TME, Dieuzeide G, Eriksen KT, Hong T, Kaltoft MS, Lengyel C, Rhee NA, Russo GT, Shirabe S, Urbancova K, Vencio S (2021) Capture: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries. Cardiovasc Diabetol 20:154. https://doi.org/10.1186/s12933-021-01344-0
doi: 10.1186/s12933-021-01344-0
pubmed: 34315481
pmcid: 8317423
Halabi A, Sen J, Huynh Q, Marwick TH (2020) Metformin treatment in heart failure with preserved ejection fraction: a systematic review and meta-regression analysis. Cardiovasc Diabetol 19:124. https://doi.org/10.1186/s12933-020-01100-w
doi: 10.1186/s12933-020-01100-w
pubmed: 32758236
pmcid: 7409497
Hostalek U, Campbell I (2021) Metformin for diabetes prevention: update of the evidence base. Curr Med Res Opin 37:1705–1717. https://doi.org/10.1080/03007995.2021.1955667
doi: 10.1080/03007995.2021.1955667
pubmed: 34281467
Feng J, Wang X, Ye X, Ares I, Lopez-Torres B, Martínez M, Martínez-Larrañaga MR, Wang X, Anadón A, Martínez MA (2022) Mitochondria as an important target of metformin: the mechanism of action, toxic and side effects, and new therapeutic applications. Pharmacol Res 177:106114. https://doi.org/10.1016/j.phrs.2022.106114
doi: 10.1016/j.phrs.2022.106114
pubmed: 35124206
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A (2021) 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42:3599–3726. https://doi.org/10.1093/eurheartj/ehab368
doi: 10.1093/eurheartj/ehab368
pubmed: 34447992
Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, Brunner-La Rocca HP, Choi DJ, Chopra V, Chuquiure-Valenzuela E, Giannetti N, Gomez-Mesa JE, Janssens S, Januzzi JL, Gonzalez-Juanatey JR, Merkely B, Nicholls SJ, Perrone SV, Piña IL, Ponikowski P, Senni M, Sim D, Spinar J, Squire I, Taddei S, Tsutsui H, Verma S, Vinereanu D, Zhang J, Carson P, Lam CSP, Marx N, Zeller C, Sattar N, Jamal W, Schnaidt S, Schnee JM, Brueckmann M, Pocock SJ, Zannad F, Packer M (2021) Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385:1451–1461. https://doi.org/10.1056/NEJMoa2107038
doi: 10.1056/NEJMoa2107038
pubmed: 34449189
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW (2022) 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice guidelines. Circulation 145:e895–e1032. https://doi.org/10.1161/cir.0000000000001063
doi: 10.1161/cir.0000000000001063
pubmed: 35363499
Tomasoni D, Fonarow GC, Adamo M, Anker SD, Butler J, Coats AJS, Filippatos G, Greene SJ, McDonagh TA, Ponikowski P, Rosano G, Seferovic P, Vaduganathan M, Voors AA, Metra M (2022) Sodium-glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction. Eur J Heart Fail 24:431–441. https://doi.org/10.1002/ejhf.2397
doi: 10.1002/ejhf.2397
pubmed: 34894038
Aimo A, Castiglione V, Borrelli C, Saccaro LF, Franzini M, Masi S, Emdin M, Giannoni A (2020) Oxidative stress and inflammation in the evolution of heart failure: from pathophysiology to therapeutic strategies. Eur J Prev Cardiol 27:494–510. https://doi.org/10.1177/2047487319870344
doi: 10.1177/2047487319870344
pubmed: 31412712
Antonucci S, Di Lisa F, Kaludercic N (2021) Mitochondrial reactive oxygen species in physiology and disease. Cell Calcium 94:102344. https://doi.org/10.1016/j.ceca.2020.102344
doi: 10.1016/j.ceca.2020.102344
pubmed: 33556741
Edmondson DE (2014) Hydrogen peroxide produced by mitochondrial monoamine oxidase catalysis: biological implications. Curr Pharm Des 20:155–160. https://doi.org/10.2174/13816128113190990406
doi: 10.2174/13816128113190990406
pubmed: 23701542
Heger J, Hirschhäuser C, Bornbaum J, Sydykov A, Dempfle A, Schneider A, Braun T, Schlüter KD, Schulz R (2021) Cardiomyocytes-specific deletion of monoamine oxidase B reduces irreversible myocardial ischemia/reperfusion injury. Free Radic Biol Med 165:14–23. https://doi.org/10.1016/j.freeradbiomed.2021.01.020
doi: 10.1016/j.freeradbiomed.2021.01.020
pubmed: 33476795
Kaludercic N, Takimoto E, Nagayama T, Feng N, Lai EW, Bedja D, Chen K, Gabrielson KL, Blakely RD, Shih JC, Pacak K, Kass DA, Di Lisa F, Paolocci N (2010) Monoamine oxidase A-mediated enhanced catabolism of norepinephrine contributes to adverse remodeling and pump failure in hearts with pressure overload. Circ Res 106:193–202. https://doi.org/10.1161/circresaha.109.198366
doi: 10.1161/circresaha.109.198366
pubmed: 19910579
Kaludercic N, Carpi A, Nagayama T, Sivakumaran V, Zhu G, Lai EW, Bedja D, De Mario A, Chen K, Gabrielson KL, Lindsey ML, Pacak K, Takimoto E, Shih JC, Kass DA, Di Lisa F, Paolocci N (2014) Monoamine oxidase B prompts mitochondrial and cardiac dysfunction in pressure overloaded hearts. Antioxid Redox Signal 20:267–280. https://doi.org/10.1089/ars.2012.4616
doi: 10.1089/ars.2012.4616
pubmed: 23581564
pmcid: 3887464
Sturza A, Leisegang MS, Babelova A, Schroder K, Benkhoff S, Loot AE, Fleming I, Schulz R, Muntean DM, Brandes RP (2013) Monoamine oxidases are mediators of endothelial dysfunction in the mouse aorta. Hypertension 62:140–146. https://doi.org/10.1161/hypertensionaha.113.01314
doi: 10.1161/hypertensionaha.113.01314
pubmed: 23670301
Sturza A, Duicu OM, Vaduva A, Danila MD, Noveanu L, Varro A, Muntean DM (2015) Monoamine oxidases are novel sources of cardiovascular oxidative stress in experimental diabetes. Can J Physiol Pharmacol 93:555–561. https://doi.org/10.1139/cjpp-2014-0544
doi: 10.1139/cjpp-2014-0544
pubmed: 25996256
Lighezan R, Sturza A, Duicu OM, Ceausu RA, Vaduva A, Gaspar M, Feier H, Vaida M, Ivan V, Lighezan D, Muntean DM, Mornos C (2016) Monoamine oxidase inhibition improves vascular function in mammary arteries from nondiabetic and diabetic patients with coronary heart disease. Can J Physiol Pharmacol 94:1040–1047. https://doi.org/10.1139/cjpp-2015-0580
doi: 10.1139/cjpp-2015-0580
pubmed: 27322151
Sturza A, Olariu S, Ionică M, Duicu OM, Văduva AO, Boia E, Muntean DM, Popoiu CM (2019) Monoamine oxidase is a source of oxidative stress in obese patients with chronic inflammation (1). Can J Physiol Pharmacol 97:844–849. https://doi.org/10.1139/cjpp-2019-0028
doi: 10.1139/cjpp-2019-0028
pubmed: 31051081
Di Matteo S, Nevi L, Overi D, Landolina N, Faccioli J, Giulitti F, Napoletano C, Oddi A, Marziani AM, Costantini D, De Rose AM, Melandro F, Bragazzi MC, Grazi GL, Berloco PB, Giuliante F, Donato G, Moretta L, Carpino G, Cardinale V, Gaudio E, Alvaro D (2021) Metformin exerts anti-cancerogenic effects and reverses epithelial-to-mesenchymal transition trait in primary human intrahepatic cholangiocarcinoma cells. Sci Rep 11:2557. https://doi.org/10.1038/s41598-021-81172-0
doi: 10.1038/s41598-021-81172-0
pubmed: 33510179
pmcid: 7844056
Ionică LN, Gaiță L, Bînă AM, Soșdean R, Lighezan R, Sima A, Malița D, Crețu OM, Burlacu O, Muntean DM, Sturza A (2021) Metformin alleviates monoamine oxidase-related vascular oxidative stress and endothelial dysfunction in rats with diet-induced obesity. Mol Cell Biochem 476:4019–4029. https://doi.org/10.1007/s11010-021-04194-2
doi: 10.1007/s11010-021-04194-2
pubmed: 34216348
Merce AP, Ionică LN, Bînă AM, Popescu S, Lighezan R, Petrescu L, Borza C, Sturza A, Muntean DM, Creţu OM (2022) Monoamine oxidase is a source of cardiac oxidative stress in obese rats: the beneficial role of metformin. Mol Cell Biochem. https://doi.org/10.1007/s11010-022-04490-5
doi: 10.1007/s11010-022-04490-5
pubmed: 36583793
Alshnbari AS, Millar SA, O’Sullivan SE, Idris I (2020) Effect of sodium-glucose cotransporter-2 inhibitors on endothelial function: a systematic review of preclinical studies. Diabetes Ther 11:1947–1963. https://doi.org/10.1007/s13300-020-00885-z
doi: 10.1007/s13300-020-00885-z
pubmed: 32715425
pmcid: 7434811
Badalica-Petrescu M, Munteanu M, Sturza A, Noveanu L, Streian C, Socaciu C, Muntean D, Timar R, Dragan S (2014) Characterization of the effects of two polyphenols-rich plant extracts on isolated diabetic human mammary arteries. Rev Chim 65:861–864
Sun XQ, Peters EL, Schalij I, Axelsen JB, Andersen S, Kurakula K, Gomez-Puerto MC, Szulcek R, Pan X, da Silva GoncalvesBos D, Schiepers REJ, Andersen A, Goumans MJ, VonkNoordegraaf A, van der Laarse WJ, de Man FS, Bogaard HJ (2021) Increased MAO-A activity promotes progression of pulmonary arterial hypertension. Am J Respir Cell Mol Biol 64(3):331–343. https://doi.org/10.1165/rcmb.2020-0105OC
doi: 10.1165/rcmb.2020-0105OC
pubmed: 33264068
Sturza A, Popoiu CM, Ionică M, Duicu OM, Olariu S, Muntean DM, Boia ES (2019) Monoamine oxidase-related vascular oxidative stress in diseases associated with inflammatory burden. Oxid Med Cell Longev 2019:8954201. https://doi.org/10.1155/2019/8954201
doi: 10.1155/2019/8954201
pubmed: 31178977
pmcid: 6501417
Merce A, Buriman DG, Lascu A, Bînă AM, Feier HB, Petrescu L, Borza C, Sturza A, Muntean DM and Crețu OM (2022) Metformin reverses the effects of angiotensin 2 in human mammary arteries by modulating the expression of nitric oxide synthases. Serbian J Exp Clin Res. https://doi.org/10.2478/sjecr-2022-0070
Sambe T, Mason RP, Dawoud H, Bhatt DL, Malinski T (2018) Metformin treatment decreases nitroxidative stress, restores nitric oxide bioavailability and endothelial function beyond glucose control. Biomed Pharmacother 98:149–156. https://doi.org/10.1016/j.biopha.2017.12.023
doi: 10.1016/j.biopha.2017.12.023
pubmed: 29253762
Ding Y, Zhou Y, Ling P, Feng X, Luo S, Zheng X, Little PJ, Xu S, Weng J (2021) Metformin in cardiovascular diabetology: a focused review of its impact on endothelial function. Theranostics 11:9376–9396. https://doi.org/10.7150/thno.64706
doi: 10.7150/thno.64706
pubmed: 34646376
pmcid: 8490502
Venu VKP, Saifeddine M, Mihara K, Faiza M, Gorobets E, Flewelling AJ, Derksen DJ, Hirota SA, Marei I, Al-Majid D, Motahhary M, Ding H, Triggle CR, Hollenberg MD (2021) Metformin prevents hyperglycemia-associated, oxidative stress-induced vascular endothelial dysfunction: essential role for the orphan nuclear receptor human nuclear receptor 4A1 (Nur77). Mol Pharmacol 100:428–455. https://doi.org/10.1124/molpharm.120.000148
doi: 10.1124/molpharm.120.000148
pubmed: 34452975
Mohammed I, Hollenberg MD, Ding H, Triggle CR (2021) A critical review of the evidence that metformin is a putative anti-aging drug that enhances healthspan and extends lifespan. Front Endocrinol (Lausanne) 12:718942. https://doi.org/10.3389/fendo.2021.718942
doi: 10.3389/fendo.2021.718942
pubmed: 34421827
McGuire DK, Shih WJ, Cosentino F, Charbonnel B, Cherney DZI, Dagogo-Jack S, Pratley R, Greenberg M, Wang S, Huyck S, Gantz I, Terra SG, Masiukiewicz U, Cannon CP (2021) Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol 6:148–158. https://doi.org/10.1001/jamacardio.2020.4511
doi: 10.1001/jamacardio.2020.4511
pubmed: 33031522
Durante W, Behnammanesh G, Peyton KJ (2021) Effects of sodium-glucose co-transporter 2 inhibitors on vascular cell function and arterial remodeling. Int J Mol Sci. https://doi.org/10.3390/ijms22168786
doi: 10.3390/ijms22168786
pubmed: 34445519
pmcid: 8396183
Uthman L, Homayr A, Juni RP, Spin EL, Kerindongo R, Boomsma M, Hollmann MW, Preckel B, Koolwijk P, van Hinsbergh VWM, Zuurbier CJ, Albrecht M, Weber NC (2019) Empagliflozin and dapagliflozin reduce ROS generation and restore NO bioavailability in tumor necrosis factor α-stimulated human coronary arterial endothelial cells. Cell Physiol Biochem 53:865–886. https://doi.org/10.33594/000000178
doi: 10.33594/000000178
pubmed: 31724838
Han JH, Oh TJ, Lee G, Maeng HJ, Lee DH, Kim KM, Choi SH, Jang HC, Lee HS, Park KS, Kim YB, Lim S (2017) The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE (-/-) mice fed a western diet. Diabetologia 60:364–376. https://doi.org/10.1007/s00125-016-4158-2
doi: 10.1007/s00125-016-4158-2
pubmed: 27866224
Fukuda T, Bouchi R, Terashima M, Sasahara Y, Asakawa M, Takeuchi T, Nakano Y, Murakami M, Minami I, Izumiyama H, Hashimoto K, Yoshimoto T, Ogawa Y (2017) Ipragliflozin reduces epicardial fat accumulation in non-obese type 2 diabetic patients with visceral obesity: a pilot study. Diabetes Ther 8:851–861. https://doi.org/10.1007/s13300-017-0279-y
doi: 10.1007/s13300-017-0279-y
pubmed: 28616806
pmcid: 5544615
Sato T, Aizawa Y, Yuasa S, Kishi S, Fuse K, Fujita S, Ikeda Y, Kitazawa H, Takahashi M, Sato M, Okabe M (2018) The effect of dapagliflozin treatment on epicardial adipose tissue volume. Cardiovasc Diabetol 17:6. https://doi.org/10.1186/s12933-017-0658-8
doi: 10.1186/s12933-017-0658-8
pubmed: 29301516
pmcid: 5753537
Park SH, Belcastro E, Hasan H, Matsushita K, Marchandot B, Abbas M, Toti F, Auger C, Jesel L, Ohlmann P, Morel O, Schini-Kerth VB (2021) Angiotensin II-induced upregulation of SGLT1 and 2 contributes to human microparticle-stimulated endothelial senescence and dysfunction: protective effect of gliflozins. Cardiovasc Diabetol 20:65. https://doi.org/10.1186/s12933-021-01252-3
doi: 10.1186/s12933-021-01252-3
pubmed: 33726768
pmcid: 7967961
Campeau MA, Leask RL (2022) Empagliflozin mitigates endothelial inflammation and attenuates endoplasmic reticulum stress signaling caused by sustained glycocalyx disruption. Sci Rep 12:12681. https://doi.org/10.1038/s41598-022-16763-6
doi: 10.1038/s41598-022-16763-6
pubmed: 35879337
pmcid: 9314417
Uthman L, Li X, Baartscheer A, Schumacher CA, Baumgart P, Hermanides J, Preckel B, Hollmann MW, Coronel R, Zuurbier CJ, Weber NC (2022) Empagliflozin reduces oxidative stress through inhibition of the novel inflammation/NHE/[Na(+)](c)/ROS-pathway in human endothelial cells. Biomed Pharmacother 146:112515. https://doi.org/10.1016/j.biopha.2021.112515
doi: 10.1016/j.biopha.2021.112515
pubmed: 34896968